AI Article Synopsis
- Nudt15 is a well-studied enzyme from the NUDIX protein family, primarily for its effects on thiopurine drugs used in cancer and inflammatory disease treatment.
- Besides its known activity on thiopurines, Nudt15 also acts on various nucleotide substrates, and there's speculation about its role in the degradation of mRNA through hydrolysis of mGDP.
- Recent research showed that Nudt15 has moderate activity with methylated forms of GDP and GTP, suggesting these can inform the design of new small molecule inhibitors targeting Nudt15.
Article Abstract
The Nudt15 enzyme of the NUDIX protein family is the subject of extensive study due to its action on thiopurine drugs used in the treatment of cancer and inflammatory diseases. In addition to thiopurines, Nudt15 is enzymatically active in vitro on several nucleotide substrates. It has also been suggested that this enzyme may play a role in 5'RNA turnover by hydrolyzing mGDP, a product of mRNA decapping. However, no detailed studies on this substrate with Nudt15 are available. Here, we analyzed the enzymatic activity of Nudt15 with mGDP, its triphosphate form mGTP, and the trimethylated counterparts (mGDP and mGTP). Kinetic data revealed a moderate activity of Nudt15 toward these methylated mononucleotides compared to the dGTP substrate. However mGDP and mGDP showed a distinct stabilization of Nudt15 upon ligand binding, in the same range as dGTP, and thus these two mononucleotides may be used as leading structures in the design of small molecule binders of Nudt15.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618335 | PMC |
| http://dx.doi.org/10.1007/s00249-023-01678-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of azathioprine in patients with Cronkhite-Canada syndrome: a case series from Peking Union Medical College Hospital.
BMC Pharmacol Toxicol
December 2024
Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
Background: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary chronic inflammatory disease characteristic of gastrointestinal polyps and ectodermal abnormalities. Corticosteroid therapy is the mainstay medication for CCS. Few studies indicated immunosuppressants might be the choices for patients with steroid refractory, steroid dependent or intolerant.
View Article and Find Full Text PDFTherapeutic Agents and Patient Characteristics Affecting Metabolism ofThiopurines in Patients with Inflammatory Bowel Disease.
Fukushima J Med Sci
December 2024
Department of Coloproctology and Gastroenterology, Aizu Medical Center Fukushima Medical University.
Objectives: In inflammatory bowel disease therapy, thiopurines have been essential. However, several reports have investigated factors affecting thiopurine metabolism to date. This study investigated factors affecting intracellular concentrations of 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) in a real-world setting.
View Article and Find Full Text PDFCoupling cellular drug-target engagement to downstream pharmacology with CeTEAM.
Nat Commun
December 2024
Science for Life Laboratory, Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, SE-141 52, Sweden.
Cellular target engagement technologies enable quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. Here, we present cellular target engagement by accumulation of mutant as a platform that can concomitantly evaluate drug-target interactions and phenotypic responses using conditionally stabilized drug biosensors. We observe that drug-responsive proteotypes are prevalent among reported mutants of known drug targets.
View Article and Find Full Text PDFContemporary and prospective use of azathioprine (AZA) in viral, rheumatic, and dermatological disorders: a review of pharmacogenomic and nanotechnology applications.
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Department of Pharmacy Practice, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Pune, Maharashtra, India.
Article Synopsis
- Azathioprine (AZA), commonly used for autoimmune disorders and organ transplants, shows potential for modern applications in viral, rheumatic, and skin diseases.
- Advances in pharmacogenomics and nanotechnology may enhance AZA's effectiveness while reducing side effects, particularly by utilizing the active metabolites 6-mercaptopurine and 6-thioguanine.
- The study suggests that personalized medicine approaches, including genetic testing and innovative drug delivery systems, can improve treatment outcomes for conditions like systemic lupus erythematosus and psoriasis.
A case of rapidly progressive hair loss due to azathioprine, and the prevalence of NUDT15 variants among Japanese patients with autoimmune blistering diseases: A single-center retrospective observational study.
J Dermatol
October 2024
Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Autoimmune blistering diseases (AIBDs), classified into pemphigus and pemphigoid, consist of relatively rare skin disorders caused by autoantibodies that target desmosomal and hemidesmosomal proteins, respectively. Although systemic corticosteroids are used as a first-line treatment for AIBDs, azathioprine is frequently co-administered as a steroid-sparing agent. Azathioprine is metabolized into thioguanine nucleotides (TGNs) which are its major active metabolites.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!